Skip to main content
Markets · Live
DJIA50,687.07▼ -1.21%S&P 5007,553.68▼ -0.74%Nasdaq26,853.98▼ -0.89%Nvidia—▼ TSMC—▼ Alphabet—▼ Bitcoin—▼ DJIA50,687.07▼ -1.21%S&P 5007,553.68▼ -0.74%Nasdaq26,853.98▼ -0.89%Nvidia—▼ TSMC—▼ Alphabet—▼ Bitcoin—▼
New York--:--
Chicago--:--
Denver--:--
Los Angeles--:--
Honolulu--:--
Anchorage--:--
Tokyo--:--
Berlin--:--
London--:--
UTC--:--

Breaking

BLOOMBERG MARKETS — Dimon Concerned Inflation May Be Sticky, Rates Go Up · Oct 6, 10:07 AM ET
STAT

STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.

Meghana Keshavan
By Meghana Keshavan· STAT News· Published · Photo: Anthony Devlin/Getty Images for AstraZeneca

Rights: fair use excerpt

STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
Reporting by Meghana KeshavanSource: STAT NewsPhoto: Anthony Devlin/Getty Images for AstraZenecaUpdated October 6, 2026
PHOTO: ANTHONY DEVLIN/GETTY IMAGES FOR ASTRAZENECA

---

Meghana Keshavan · STAT News · Photo: Anthony Devlin/Getty Images for AstraZeneca

Source & Credit

Reporting and photography credited as noted above. Originally published by STAT News.

Members only

Checking your membership…